AIDS Therapies (MKC-442)

Preliminary Results Reported for MKC-442 Anti-HIV Drug

Published in AIDS Weekly, February 3rd, 1997

Preliminary clinical data on the anti-HIV drug MKC-442 (Triangle Pharmaceuticals, Inc., Durham, North Caroline) were presented at the Fourth Conference on Retroviruses and Opportunistic Infections, held in Washington, D.C., January 22-25, 1997.

The data were from an ongoing Phase Ib/IIa double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of repeated multiple oral doses of MKC-442 in HIV infected patients. A total of 26 patients were treated for up to two months.

Doses ranging from 100 to 350 mg twice a day were given to groups of six patients at each dosage level and additional patients currently are entering the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-02-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry